Charles River Laboratories
Meeting with Management 2021

Advancing human health and creating healthier lives

At Charles River, we provide products and services to support the discovery, non-clinical development, and safe manufacture of novel drugs and therapeutics. As the only contract research organization (CRO) with an integrated portfolio that spans the drug research process from target discovery through non-clinical development and manufacturing solutions, we partner with our clients to deliver innovative, safe, and effective therapies, as quickly and efficiently as possible.

Charles River is committed to providing the scientific expertise our clients require when and where they need it. We have built upon our original core competency of research model technologies to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, and a suite of products and services to support our clients’ manufacturing activities. Our products and services are provided through three business segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing. With approximately 19,000 employees located in over 100 facilities across 20 countries, we are passionate about our role in improving the quality of people’s lives and we are proud to have worked on more than 80% of the FDA drug approvals in each of the last three years. The work that we do is essential to help our clients discover and develop new drugs for the patients who need them.

Stream

Webcast Replay

May 27, 2021
8:30 AM - 11:30 AM ET

Watch Now

Presentation Slides

Meeting with Management 2021

Agenda

May 27, 2021
8:30 AM - 11:30 AM ET
Opening Remarks
Todd Spencer, Corporate Vice President, Investor Relations
Video On Demand Presentation
Strategic Overview
Jim Foster, Chairman, President & CEO
Video On Demand Presentation
Financial Overview
David Smith, Corporate Executive Vice President & CFO
Video On Demand Presentation
Questions & Answers
Cell & Gene Therapy Scientific Overview
Dr. Daniel Smith, Executive Director, Global Cell and Gene Therapy Portfolio
Video On Demand Presentation
C&GT Strategic Vision and Discovery & Safety Assessment
Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Solutions, and Avian Vaccine Services
Video On Demand Presentation
Manufacturing Solutions: Biologics Testing Solutions
Kerstin Dolph, Corporate Vice President, Biologics Solutions
Video On Demand Presentation
Manufacturing Solutions: Cell & Gene Therapy CDMO Services
Mike Austin, Corporate Vice President, Cell and Gene Therapy CDMO
Video On Demand Presentation
Research Models & Services
Dr. Colin Dunn, Corporate Senior Vice President, Global Research Models & Services
Video On Demand Presentation
Technology Partnerships
Dr. Julie Frearson, Corporate Vice President, Strategic Alliances
Video On Demand Presentation
Questions & Answers
Closing Remarks
Jim Foster
Video On Demand

Presentation

Speakers

2020 Fiscal Year Results

Financial
Highlights

15%

Revenue Growth

2016-2020 CAGR

16%

Non-GAAP EPS Growth

2016-2020 CAGR

5-year Compound Annual Growth Rates. See ir.criver.com for reconciliations of Non-GAAP to GAAP results.

15%

Operating Cash Flow Growth

2016-2020 CAGR

10%

Free Cash Flow Growth

2016-2020 CAGR

5-year Compound Annual Growth Rates. See ir.criver.com for reconciliations of Non-GAAP to GAAP results.

$2.9B

annual revenue

11.5%

reported revenue growth

7.0%

organic revenue growth

See ir.criver.com for reconciliations of Non-GAAP to GAAP results.

14.8%

GAAP Operating Margin

20.0%

Non-GAAP Operating Margin

100 bps increase from fiscal 2019

See ir.criver.com for reconciliations of Non-GAAP to GAAP results.

$7.20

GAAP EPS

$8.13

Non-GAAP EPS

20.8% increase from fiscal 2019

See ir.criver.com for reconciliations of Non-GAAP to GAAP results.

64%

One-year Total Shareholder

Return for fiscal 2020

25%

five-year annualized total shareholder return (2016-2020)

INVESTOR RESOURCE

Website Help

Should you have any questions or require assistance please contact the Q4 Inc. Investor Day support team

investordays@q4inc.com